Drug Trial Radar · NCT06057038
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
8
Actual
Start
Nov 24, 2023
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluating GEN1042 will include multiple parts. In this study, GEN1042 alone (phase 1a) or GEN1042 in combination with other anticancer drug(s) (phase 1b) will be evaluated in Japanese participants. The main purpose is to assess the safety and tolerability of GEN1042 monotherapy or GEN1042 in combination in Japanese study participants with cancer.
Conditions
- Malignant Solid Tumor
Interventions
GEN1042Biological
Intravenous
PembrolizumabDrug
Intravenous
CisplatinDrug
Intravenous
CarboplatinDrug
Intravenous
5-FluorouracilDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: During the first cycle (Cycle length = 21 days)
- Percentage of Participants with Adverse Events (AEs)Time frame: From first dose until the end of the treatment (approximately 3 years)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center East
Kashiwa, Japan
National Cancer Center Hospital
Tokyo, Japan
Tokyo Medical University Hospital
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.